Champions Biotechnology, Inc. Appoints New Board Members and Forms Management Team
ARLINGTON, Va., April 1, 2008 / PRNewswire-FirstCall / - champions of biotechnology, Inc, a company that is in preclinical development platforms advanced tumor-specific data and to improve the value of drugs of oncology, today announced the appointment of new members of the board of directors and the creation of an experienced management team, as he prepares the development of their activities.
Abba Poliakoff Stancic David and Ana were appointed as new independent directors in the board of directors of the company who, under the chairmanship of Dr. David Sidransky. The Board of Directors also an audit, nomination and corporate governance and Compensation Committee. The company expects other names of the committee members independent of the future correctly to these committees as part of the growth initiatives and the promotion of its plans for implementation of a state of the art ” Corporate Governance “of the regime.
The company has also made a new management team. Douglas D. Burkett, Ph.D. Was appointed to act as company president, Manuel Hidalgo, MD, Ph.D., is appointed to serve as Chief Scientific Officer, and education is Durwood as Chief Financial Officer. James M. Martel, the company is the founder and director has been appointed Chief Administrative Officer and transmits the positions of CEO, President and CFO.
“We are very pleased with this excellent individuals in our Board and the management team as we develop our platform preclinical and opportunities that we believe, to put in place,” said Dr. David Sidransky, Chairman of Board of champions of biotechnology, Inc. “We are grateful that Dr. Manuel Hidalgo, which has, the Board of Directors as a director in the head of our scientific efforts as Chief Scientific Officer, past and to thank the Member of the Board, Durwood and education of Michael Tomic Board for their commitment to service companies. I look forward to working closely with Dr. Doug Burkett, as he leads management to achieve our goal to set itself up as the world leader in preclinical studies using specific platforms of the tumor and data. “Castle Dr. Sidransky.
D Douglas Burkett, Ph.D. , Commented: “I accompanied and worked with Dr. David Sidransky for almost a decade, and I am delighted for the opportunity, during the implementation of its vision for the champions of a world leader biotechnology. Please read the contract of the company’s new website Www.championsbiotechnology.com for an overview of our business. ”
The new committee members:
Abba Poliakoff David is a member of the law firm Gordon, thin blade, Rothman, Hoff Berger & Hollander, LLC, in Baltimore, Maryland, Firm-president of the Business Division, and a member of the company’s Electronic Discovery Practice Group. Mr JD Poliakoff received her degree, magna cum laude, in 1977 from the University of Baltimore Law School, where he was editor of the University of Baltimore Law Review and Associate Editor, the Forum of the Law Journal. According to the legislation of the school, Mr. Poliakoff has joined the staff of the US Securities and Exchange Commission in Washington, DC, where he was a prosecutor in chief of the division Finance Corporation. Mr. Poliakoff is currently a member of the Maryland State Bar Association’s Business Law Section and former president of the securities commission. Previously, he was a member of the Business Review article Regulations Committee of the commission for the revision of the Maryland Annotated Code. It was in the United States, Chambers, Leading Business Lawyers, since its inception in 2003. Mr. Poliakoff is a board member of the Greater Baltimore Technology Council (GBTC) and chairman of the Legislative Council. He is a past president of the Maryland Business & Technology Coalition, a member of the Technology Council of Maryland, and is a member of the MIT Enterprise Forum. Mr. Poliakoff is currently the president of the Maryland Israel Development Center, a joint venture between the State of Israel and the State of Maryland, thanks to the cooperation Maryland Department of Business and Economic Development and the Israeli Ministry of Industry and trade.
Ana I. Stancic since March 2008 as Chief Financial Officer of the Aureon Laboratories, Incorporated ( “Aureon”), a company dedicated to diagnostic oncology for the development of the prevention and treatment of cancer personalized, laboratory diagnosis of reference and clinical research. Prior to joining Aureon, Ms. Stancic was Executive Vice President and Chief Financial Officer at OMRIX Biopharmaceuticals, Inc. Prior to entering OMRIX, Ms. Stancic as Senior Vice President, Finance at ImClone Systems, Inc. ( “ImClone”), a comprehensive approach Oblige Biopharmazeutisches businesses, the promotion of oncology care, where she was responsible for the finance department ImClone, information technology and internal audit. Ms. Stancic ImClone joined as Vice President, Controller and Chief Accounting Officer in 2004. Prior to her arrival at ImClone, she was vice president and controller at Savient Pharmaceuticals, Inc., from 2003 to February 2004. Ms. Stancic was Vice President and Chief Accounting Officer at Ogden Corporation from 1999 to 2002 and Chief Financial Officer regional buses Care, Inc., from 1997 to 1999. Ms. Stancic began his career in 1985 with Price Waterhouse Coopers, in the area of Insurance, where they responsible for the national and international society in the pharmaceutical industry and services. Ms. Stancic is Certified Public Accountant and has an MBA from Columbia Business School.
New Management Team:
Chairman: D. Douglas Burkett, Ph.D. Executive served as a consultant to help businesses in the development and implementation of its strategy and business plan, to be President. Mr. Burkett served as President, Chief Executive Officer and President of Zila, Inc. from 2002 to 2007 and carried out a strategic transformation of Zila in the detection of cancer. He proceeded to the FDA approval, the start-up and growth of ViziLite Plus, a product oral cancer screening, and the establishment of the first insurance reimbursement for products oral cancer screening in the United States . Mr. Burkett has held several management positions at Zila from 1995 to 2002, he was responsible for the technical operation Zila, its production subsidiaries, its Pharmaceuticals business and enterprise development. From the beginning of his career, he has directed the establishment of an R & D lab, the center of pharmaceutical production, compliance and legal unit of the team reached a rare “no shortage” of Inspection FDA approval. Mr. Burkett is the inventor, and many patent applications and delivers medicines and new methods for cancer detection. It is quoted in major publications such as the Wall Street Journal about his pioneering efforts in the early detection of cancer of the oral cavity. Prior to joining Zila, Mr. Burkett was sent to the Arizona State University Cancer Research Institute, where he, in collaboration with the National Cancer Institute, of the synthesis and study presentations potential drugs for the treatment of cancer. Before working at Novartis, ASU, develops and manufactures drugs for a pharmaceutical company private. Mr. Burkett get B.S. In the chemistry of Missouri Western State College in 1987 and a Ph.D. In the organic chemistry from Arizona State University in 1994.
Related Articles
You Better Shop Around
Unter Treasury Secretary Henry Paulson's vor kurzem angekündigten Pläne zur Überholung US finanziellen Regelungen, gibt es noch eine Änderung grundlegende, die die Vorteile unmittelbare für die Verbraucher: die Amerikaner zum Shop bundesweit für ihre Versicherungspolicen. Nach dem derzeitigen System, Staat regelt jeder seine eigene Versicherung. Daher ist eine Firma, Pennsylvania verkaufen
Shaky finances Put blue cross on the test bench
For nearly half a century, Blue Cross Blue Shield, and appreciated the reputation of a well-managed non-profit service network as the nation's largest source of private health insurance. But in recent weeks, investigators federal and state authorities, not indications of questionable business practices. They range from the destruction of outstanding claims
Tyler appointed Commissioner Maryland
Dir Maryland Martin O'Malley appointed lawyer and adviser Ralph S. Tyler State insurance commissioner responsible for overseeing the regulation of Maryland's $ 26 billion insurance. Tyler was as Chief Legal Counsel for the O'Malley-Brown, Administrator. Peggy is to replace Tyler Watson, who served as interim Commissioner Steven Orr left. "I welcome the services
Maryland car takes Task Force
The Maryland Insurance is convening its Auto Insurance task force to study the price for Urban Areas today, Oct 18, Prince George's Community College, Largo Student Center, Conference Room 2 The Task Force was invited to learn what other countries have done so for the problem of high price of auto
Spending computer setback for the exploitation of insurance
When he heard that insurers increase accountability for Sport Utility Vehicles, David Gregorino was angry. Mr. Gregorino, 42, a delivery office in Charlotte, NC, readers, a full-size Chevrolet Tahoe, drew from its insurers and industry officials complain. He wants even on the possible participation in the crash tests of sport business
To promote laws automatic alarm, but they can not worthwhile
It seemed a small technical issue, an amendment of section 167-f (12) of the New York State Insurance Law, and it happened a decade ago, very quiet. But since then, all New Yorkers heard its consequences, often around 2 hours into the night. The new law requires insurance companies to discounts
Hospitals' 'hope coaches'
Salaries of cancer had Marina Pena's when the hairs of the head completely in a few sprigs büscheligen. Peinlich, she hid under a caustic polar cap blue, slightly adapted to the 85 years of a grandmother. Anne McNerney knew how to feel Pena. Years ago, the time to achieve its own
Maryland Sets a clean bill of health for the costs of Wal-Mart
Wal-Mart has attracted strong criticism because it insures less than half of its USA of the workforce and because its employees routinely show, as many people from other retailers The government Medicaid roles. In response to these complaints, the company conducted a new health plan late last year, with premiums as
ACA Capital CEDES supervisors
A recent state of regulation has ACA Capital Holdings Inc. to continue their operating costs and insurance bond, but the solution should be temporary, as analysts doubt the company can survive long term. ACA has expressed its readiness on Maryland supervision of regulatory authorities, the company said in a Securities and
An innovation in health care opens at CVS pharmacy stores in the triangle
Raleigh, NC, PRNewswire - Fast, comfortable and quality of health care has come, the triangle with the opening six minutes Clinic in health centres CVS / pharmacy locations throughout Raleigh-Durham-Chapel Hill region Metropolitan. The first retail-based health care in the Central North Carolina, minute Clinic is open Monday to Friday.